Japan Tissue Engineering Co., Ltd. (TYO:7774)
786.00
+4.00 (0.51%)
Aug 6, 2026, 11:30 AM JST
Japan Tissue Engineering Revenue
Japan Tissue Engineering had revenue of 766.85M JPY in the quarter ending June 30, 2026, with 79.85% growth. This brings the company's revenue in the last twelve months to 2.52B, up 3.43% year-over-year. In the fiscal year ending March 31, 2026, Japan Tissue Engineering had annual revenue of 2.18B, down -11.12%.
Revenue (ttm)
2.52B
Revenue Growth
+3.43%
P/S Ratio
12.59
Revenue / Employee
12.62M
Employees
200
Market Cap
31.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.18B | -273.00M | -11.12% |
| Mar 31, 2025 | 2.46B | -59.00M | -2.35% |
| Mar 31, 2024 | 2.51B | 482.00M | 23.72% |
| Mar 31, 2023 | 2.03B | -71.00M | -3.38% |
| Mar 31, 2022 | 2.10B | -154.00M | -6.82% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.82B |
| Heartseed | 3.03B |
| ReproCELL | 2.23B |
| AnGes | 908.00M |
| Stella Pharma | 323.00M |
| SUSMED,Inc. | 274.00M |
| Cuorips | 212.00M |
| Healios K.K. | 74.00M |